Almac recorded pre-tax profits of £19.2m in 2013, up around 30 per cent on the previous year, it has announced.
The Seagoe company also saw turnover increase, up by eight per cent from £300m to £325m.
Around 3,400 people now work for Almac globally, with over 2,000 based at its Portadown headquarters.
Alan Armstrong, CEO of Almac, said, “Our long term objective is to be the leader in our chosen markets and following another successful year I’m pleased to report that we are showing sustained progress in reaching this goal.
“2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13m investment in cancer research projects with Queen’s University and signed a $9m deal with Genomic Health securing the rights to further develop and commercialise our breast cancer test.
“We have continued to invest in research and development and capital programmes and this year is set to be another interesting one both at our headquarters in Craigavon and globally, following the opening of our new offices in Asia, and looking ahead to the launch of our new facility in Singapore early next year.”
Almac recently opened regional hubs in Singapore and Japan.